Sustained imaging response and hearing preservation with low-dose bevacizumab in sporadic vestibular schwannoma

Neuro Oncol. 2019 Jun 10;21(6):822-824. doi: 10.1093/neuonc/noz051.

Authors

Matthias A Karajannis¹, Mari Hagiwara², Mark Schreyer³, Sofia Haque³

Affiliations

¹ Pediatric Neuro-Oncology Service, Department of Pediatrics, Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York.
² Department of Radiology, NYU Langone Health, New York, New York.
³ Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.

No abstract available

Keywords: bevacizumab; hearing loss; vestibular schwannoma.

Publication types

Case Reports

MeSH terms

Antineoplastic Agents, Immunological / therapeutic use*
Bevacizumab / therapeutic use*
Female
Hearing Loss / pathology
Hearing Loss / prevention & control*
Humans
Magnetic Resonance Imaging / methods*
Middle Aged
Neuroma, Acoustic / drug therapy*
Neuroma, Acoustic / pathology
Prognosis

Substances

Antineoplastic Agents, Immunological
Bevacizumab